Welcome to our dedicated page for Forte Biosciences news (Ticker: FBRX), a resource for investors and traders seeking the latest updates and insights on Forte Biosciences stock.
Forte Biosciences Inc (FBRX) is a clinical-stage biopharmaceutical company developing FB-102, a novel therapeutic candidate targeting autoimmune conditions including graft-versus-host disease, vitiligo, and alopecia areata. This dedicated news hub provides real-time updates on preclinical advancements, regulatory milestones, and strategic initiatives shaping the company's research trajectory.
Access authoritative reports on key developments including trial design updates, intellectual property filings, and partnership announcements. Our curated news collection serves investors and researchers seeking to track FBRX's progress in immunomodulation therapies without promotional bias.
Content highlights include:
• Preclinical study results
• Research collaboration updates
• Financial performance reports
• Management commentary
Bookmark this page for streamlined access to verified FBRX developments. Regularly updated to reflect the company's evolving position in autoimmune therapeutics research.
Forte Biosciences, Inc. (NASDAQ: FBRX) reported its first quarter 2021 results on May 10, highlighting significant progress in its clinical trial for FB-401, targeting atopic dermatitis. The trial has completed enrollment with 154 subjects, with topline results expected in Q3 2021. The company ended Q1 2021 with approximately $54.8 million in cash, sufficient for operations over the next year. Operating expenses rose due to increased R&D and administrative costs, leading to a net loss of $4.8 million, or $0.36 per share.
Forte Biosciences, Inc. (NASDAQ: FBRX) will disclose its first quarter 2021 results and provide a business update on May 10, 2021. The conference call will take place at 4:30 PM Eastern Time, accessible via phone or webcast. Forte is focused on developing FB-401, a live biotherapeutic for treating inflammatory skin diseases, particularly atopic dermatitis. A Phase 1/2a study has shown promising safety and efficacy across age groups. However, the company notes the potential risks associated with clinical development and obtaining necessary capital.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced its fourth quarter and full year 2020 results on March 24, 2021. The company completed enrollment of 154 subjects in its clinical trial for FB-401, which received FDA Fast Track designation. Additionally, Forte raised $46 million through a public offering in November. As of December 31, 2020, the company's cash and cash equivalents totaled $58.8 million, sufficient for operations for at least 12 months. R&D expenses surged to $10 million, driven by clinical development costs, while 2020 losses per share were reported at $6.32.
Forte Biosciences, Inc. (NASDAQ: FBRX) will announce its 4Q and full-year 2020 results on March 24, 2021, at 8:30 AM ET, accompanied by a business update. The conference call can be accessed via phone or a webcast link provided in the release. Forte is developing FB-401, a live biotherapeutic for inflammatory skin diseases, with a clinical trial for pediatric atopic dermatitis currently in progress. This initiative addresses a significant unmet medical need in this demographic.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Chardan Annual Microbiome Medicines Summit on March 8, 2021. A webcast of the presentation will be available at this link at 1:00 PM Eastern Time, with a replay accessible until March 15, 2021. Forte is developing a live biotherapeutic, FB-401, for treating inflammatory skin diseases like atopic dermatitis in patients aged 2 and older, addressing significant unmet needs in this area.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Cowen Annual Health Care Conference on March 1, 2021. A webcast is scheduled for the same day at 4 PM ET, accessible via the company's website. Forte is developing FB-401, a live biotherapeutic for inflammatory skin diseases, targeting atopic dermatitis with significant unmet needs, particularly in pediatric patients. FB-401 has completed Phase 1/2a trials, and a new multi-center trial for various age groups is underway, expected to enhance treatment options.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced the issuance of equity inducement awards, granting 35,000 shares of common stock to new non-executive employees as a hiring incentive. The awards will vest over four years, with 25% vesting after one year and the remaining shares vesting monthly. These awards are issued under the 2020 Inducement Equity Incentive Plan and follow NASDAQ Listing Rule 5635(c)(4). Forte is developing FB-401 for treating inflammatory skin diseases, having completed Phase 1/2a trials and currently pursuing Phase 2 trials, particularly for pediatric patients with atopic dermatitis.
Forte Biosciences, Inc. (NASDAQ: FBRX), a clinical-stage biopharmaceutical company, announced that CEO Paul Wagner, Ph.D., will present at the Evercore ISI Annual HealthCONx Conference on December 3, 2020, at 11:20 AM ET. The presentation will be accessible via a webcast, which can be found on the company's investor relations page. Forte is focused on developing its live biotherapeutic, FB-401, for inflammatory skin diseases like atopic dermatitis, having recently initiated a clinical trial to assess its efficacy in patients aged 2 years and older.
Forte Biosciences, Inc. (NASDAQ: FBRX) announces the approval of an equity inducement award under NASDAQ rules, granting 25,000 shares of common stock to a new non-executive employee. The award vests over four years, with 25% vesting after the first year and the remainder in monthly increments. This inducement aims to attract talent in a competitive market. Forte is advancing its lead product, FB-401, for inflammatory skin diseases, having initiated a Phase 2 trial to address unmet needs in pediatric and adult patients with atopic dermatitis.
Forte Biosciences, Inc. (NASDAQ: FBRX) announced that CEO Paul Wagner, Ph.D., will present at the Stifel 2020 Virtual Healthcare Conference on November 18, 2020, from 2:40 to 3:10 PM ET. A webcast of the presentation will be accessible via Forte’s website and will remain available until November 25th. The company is focused on developing FB-401, a live biotherapeutic for inflammatory skin diseases, particularly atopic dermatitis. The drug has completed Phase 1/2a trials and a new multi-center trial is expected to enroll patients from age 2 and older.
